Prescription vs OTC Hearing Aids: What Adults With Mild to Moderate Hearing Loss Need to Know
A JAMA Insights review breaks down how hearing aids work, their limits, and whether OTC devices stack up against prescription options.
Summary
Hearing loss affects millions of adults and is increasingly linked to cognitive decline, social isolation, and reduced quality of life. A new JAMA Insights piece examines hearing aids for those with mild to moderate hearing loss, covering how these devices work, their practical limitations, and the growing landscape of over-the-counter options now available without a clinical visit. Since the FDA cleared OTC hearing aids in 2022, adults have more choices but also more complexity in selecting appropriate devices. The review compares prescription hearing aids fitted by audiologists with consumer OTC alternatives, offering guidance on which populations benefit most from each pathway. For longevity-focused clinicians and health-conscious adults alike, addressing hearing loss early is increasingly viewed as a modifiable risk factor for dementia and accelerated aging.
Detailed Summary
Hearing loss is one of the most prevalent yet undertreated sensory conditions in adults worldwide. Beyond its obvious impact on communication, untreated hearing loss is now recognized as a significant risk factor for cognitive decline, depression, and social isolation — all of which accelerate biological aging. A timely JAMA Insights review by De Sousa and Swanepoel addresses the practical landscape of hearing aids for adults experiencing mild to moderate hearing loss, the population most likely to delay treatment.
The review examines the fundamental mechanics of how hearing aids amplify and process sound, as well as the real-world limitations these devices carry — including background noise challenges, device comfort, and the learning curve associated with consistent use. These limitations help explain why adoption rates remain low even among those who clearly qualify.
A central focus is the comparison between prescription hearing aids, which are fitted and calibrated by licensed audiologists, and over-the-counter devices, which became federally regulated and widely available in the United States after the FDA's 2022 ruling. OTC devices lower cost and access barriers dramatically but may not deliver equivalent outcomes for all users.
The clinical implications are significant. Physicians, particularly those in primary care and geriatrics, are increasingly positioned as first-line screeners for hearing loss. Early identification and appropriate device referral — whether OTC or prescription — may reduce downstream risks including dementia progression and falls.
For longevity-oriented readers, hearing health fits squarely into the modifiable risk factor framework. Addressing mild hearing loss proactively, rather than waiting for significant impairment, aligns with broader strategies for preserving cognitive function and social engagement into older age. The review underscores that no single device fits all patients and individualized guidance remains essential.
Key Findings
- OTC hearing aids are now a legitimate lower-cost option for adults with mild to moderate hearing loss since the 2022 FDA ruling.
- Prescription hearing aids offer individualized fitting by audiologists, which may improve outcomes for complex hearing profiles.
- Untreated hearing loss is a recognized modifiable risk factor for cognitive decline and social isolation.
- Device limitations like background noise processing and comfort remain barriers to consistent hearing aid use.
- Early intervention in mild hearing loss stages is preferable to waiting for significant impairment.
Methodology
This is a JAMA Insights review article, not an original clinical trial. It synthesizes current evidence and clinical guidance on hearing aid options for adults with mild to moderate hearing loss. The exact body of literature reviewed is not detailed in the available abstract.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; specific evidence cited in the review and detailed recommendations cannot be fully assessed. The Insights format suggests this is a narrative overview rather than a systematic review or meta-analysis, which may limit the strength of its evidence base. The clinical applicability of OTC device recommendations may vary by country, as regulatory frameworks differ outside the United States.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.